ABSTRACT
As a general rule, for every 10,000 molecules screened in a given program in the laboratory, only one will survive to launch. To minimize costs, companies need to catch potential failures, due either to lack of clinical effect or toxicity, in the early discovery phase, long before they reach patients. Experimental Therapeutics introduces the dynami
TABLE OF CONTENTS
part |1 pages
Section 1 Drug Discovery and Development
part |1 pages
Section 2 Clinical Pharmacology
part |1 pages
Section 3 Novel Therapies